A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
Authors
Bedarf JR, Romano S, Heinzmann SS, Duncan A, Traka MH, Ng D, Segovia-Lizano D, Simon MC, Narbad A, Wüllner U, Hildebrand F
Journal
NPJ Parkinson's disease
Year
2025
Current treatment of Parkinson's Disease (PD) remains symptomatic, and disease-modifying approaches are urgently required. A promising approach is to modify intestinal microbiota and key metabolites of bacterial fermentation: short-chain fatty acids (SCFA), which are decreased in PD. A prospective, controlled pilot study (DRKS00034528) was conducted on 11 couples (PD patient plus healthy spouse as control (CO)). Participants followed a 4-week diet rich in dietary fibre, including intake of the prebiotic Lactulose. Gut metagenomes, faecal and urinary metabolites, and clinical characteristics were assessed. The dietary intervention significantly augmented faecal SCFA and increased Bifidobacteria spp., reducing PD-related gastrointestinal symptoms. The pre-existing bacterial dysbiosis in PD (depletion of Blautia, Dorea, Erysipelatoclostridium) persisted. Bacterial metabolite composition in faeces and urine positively changed with the intervention: Brain-relevant gut metabolic functions involved in neuroprotective and antioxidant pathways, including S-adenosyl methionine, glutathione, and inositol, improved in PD. These promising results warrant further investigation in larger cohorts.
Experiment 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Subjects
- Location of subjects
- Germany
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to diet Response to diet,response to diet
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy spouses after prebiotics (CO group)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Parkinson's Disease patients after prebiotics (PD group)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patient diagnosed with parkinson disease after prebiotics.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 10
- Group 1 sample size Number of subjects in the case (exposed) group
- 10
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 Months
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- increased
- Richness Number of species
- increased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Fig 2E
Description: Several genera were markedly reduced in the PD group after prebiotics, paralleled by several trends
Abundance in Group 1: increased abundance in Parkinson's Disease patients after prebiotics (PD group)
| NCBI | Quality Control | Links |
|---|---|---|
| Christensenellales |
Revision editor(s): Shulamite
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Fig 2E
Description: Several genera were markedly reduced in the PD group after prebiotics, paralleled by several trends
Abundance in Group 1: decreased abundance in Parkinson's Disease patients after prebiotics (PD group)
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia ABlautia A | ||
| Dorea | ||
| Thomasclavelia | ||
| Anaerovoracaceae | ||
| Eubacterium IEubacterium I |
Revision editor(s): Shulamite, KateRasheed
Experiment 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Health spouse (CO )before prebiotics
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Healthy spouse (CO) after prebiotics
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Healthy spouses who do not have Parkinson's disease
Lab analysis
Statistical Analysis
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- decreased
- Richness Number of species
- decreased
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Supplementary Fig 3C
Description: Before vs after comparisons (Wilcoxon signed-rank test revealed that several Bifidobacteria spp. increased after prebiotics boxplots show a relative abundance of taxa. n=4 were also enriched in CO individuals.
Abundance in Group 1: increased abundance in Healthy spouse (CO) after prebiotics
| NCBI | Quality Control | Links |
|---|---|---|
| Bifidobacterium adolescentis | ||
| Bifidobacterium breve | ||
| Bifidobacterium longum | ||
| Bifidobacterium pseudocatenulatum |
Revision editor(s): Shulamite, KateRasheed
Experiment 3
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Parkinson's disease IDIOPATHIC PARKINSON DIS,Idiopathic Parkinson Disease,Idiopathic Parkinson's Disease,IDIOPATHIC PARKINSONS DIS,Idiopathic PD,LEWY BODY PARKINSON DIS,Lewy Body Parkinson Disease,Lewy Body Parkinson's Disease,Paralysis agitans,paralysis agitans,PARKINSON DIS,PARKINSON DIS IDIOPATHIC,Parkinson disease,Parkinson Disease, Idiopathic,Parkinson syndrome,Parkinson's,Parkinson's disease,Parkinson's disease (disorder),Parkinson's disease NOS,Parkinson's disease NOS (disorder),Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinson's syndrome,Parkinsonian disorder,Parkinsonism, Primary,Parkinsons,PARKINSONS DIS,PARKINSONS DIS IDIOPATHIC,PARKINSONS DIS LEWY BODY,Parkinsons disease,Primary Parkinsonism,parkinson's disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- PD before prebiotics
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- PD after prebiotics
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Parkinson's disease patient after prebiotics.
Lab analysis
Statistical Analysis
- Matched on Factors on which subjects have been matched on in a case-control study
- Not specified
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Supplementary Fig. 3c
Description: Before-vs.-after comparisons (Wilcoxon signed-rank test) revealed that several Bifidobacteria spp. increased after prebiotics. Boxplots show a relative abundance of taxa. n=6 Bifidobacteria spp. were the only sign. different in PD (Strept. Thermophilus, UMGS1975).
Abundance in Group 1: increased abundance in PD after prebiotics
Revision editor(s): Shulamite
Signature 2
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Supplementary Fig. 3c
Description: Before-vs.-after comparisons (Wilcoxon signed-rank test) revealed that several Bifidobacteria spp. increased after prebiotics. Boxplots show a relative abundance of taxa. n=6 Bifidobacteria spp. were the only sign. different in PD (Strept. Thermophilus, UMGS1975).
Abundance in Group 1: decreased abundance in PD after prebiotics
| NCBI | Quality Control | Links |
|---|---|---|
| Streptococcus thermophilus |
Revision editor(s): Shulamite
Experiment 4
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to diet Response to diet,response to diet
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Health spouse (CO )before prebiotics
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Parkinson's Disease before prebiotics
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients diagnosed with Parkinson's disease before prebiotics.
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 Months.
Lab analysis
Statistical Analysis
- Matched on Factors on which subjects have been matched on in a case-control study
- age
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Reviewed Marked as Reviewed by Svetlana up on 2025-4-23
Source: Fig 2E
Description: Several genera were markedly reduced in the PD group before prebiotics, paralleled by several trends
Abundance in Group 1: decreased abundance in Parkinson's Disease before prebiotics
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia ABlautia A |
Revision editor(s): Shulamite
Retrieved from "https://bugsigdb.org/w/index.php?title=40180909&oldid=196010"
